A Randomised Double-blind, Double-dummy Parallel Group Study to Compare the Efficacy and Safety of Fluticasone Propionate / Formoterol Fumarate (Flutiform(R)) 500/20 microg BID and 250/10 microg BID Versus Salmeterol / Fluticasone (Seretide(R)) 50/500 microg BID in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Trial Profile

A Randomised Double-blind, Double-dummy Parallel Group Study to Compare the Efficacy and Safety of Fluticasone Propionate / Formoterol Fumarate (Flutiform(R)) 500/20 microg BID and 250/10 microg BID Versus Salmeterol / Fluticasone (Seretide(R)) 50/500 microg BID in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
Phase of Trial: Phase II/III

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Formoterol/fluticasone propionate (Primary) ; Salmeterol/fluticasone propionate
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Mundipharma Research
  • Most Recent Events

    • 27 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 21 Mar 2017 Primary endpoint has been met. (Average pre-dose FEV1), according to a Vectura media release.
    • 13 May 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top